Swiftmerge Acquisition Corp. (IVCP)
| Market Cap | 74.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 2.60M |
| Shares Out | 6.84M |
| EPS (ttm) | 0.09 |
| PE Ratio | 120.44 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 212 |
| Open | 10.83 |
| Previous Close | 10.83 |
| Day's Range | 10.83 - 10.83 |
| 52-Week Range | 10.00 - 12.20 |
| Beta | 0.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About IVCP
Swiftmerge Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus its search of target in the consumer industry. The company was incorporated in 2021 and is based in Toluca Lake, California. [Read more]
Financial Performance
Financial StatementsNews
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
NEW YORK & VERO BEACH, Fla.--(BUSINESS WIRE)---- $ipo #Consumer--HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular ther...
HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
NEW YORK & VERO BEACH, Fla.--(BUSINESS WIRE)---- $health #Consumer--NASDAQ IVCP Swiftmerge Acquisition Corp (“Swiftmerge”), a $225 million innovative healthcare investment corporation and a special pu...